Day: April 8, 2020
Helsinki, Finland – April 08, 2020 – SSH.COM has been awarded roughly €750,000 in grant-based funding by the European Union and Business Finland for further development of the PrivX product. The funding is a part of the European ECSEL Joint Undertaking established in 2014.SSH.COM estimates that the funding will commence during Q3/2020 after customary preparations are concluded and the agreements are signed. The funding helps take PrivX development further and supports, in particular, the development of machine-to-machine, automation, and IIoT (Industrial Internet of Things) features of PrivX.The funding will be accounted for as a reduction in capitalized product development costs and recognized by way of reduced depreciations. A portion of the funding will be recognized under other operating income from 2020 to 2022 in proportion with...
Euroopan unioni ja Business Finland ovat myöntäneet tuotekehitysrahoitusta SSH.COM:ille PrivX®:n jatkokehitykseen
Written by Customer Service on . Posted in Public Companies.
Helsinki – 8.4.2020 – Euroopan Unioni ja Business Finland ovat myöntäneet SSH.COM:ille noin €750,000 euroa tuotekehitysavustusta PrivX-tuotteen jatkokehitystä varten. Rahoitus on osa vuonna 2014 käynnistettyä EU:n ECSEL Joint Undertaking -ohjelmaa.SSH.COM arvioi rahoituskauden alkavan kuluvan vuoden kolmannen vuosineljänneksen aikana, kun normaalit prosessiin liittyvät valmistelut on saatu päätökseen ja rahoitukseen liittyvät sopimukset on allekirjoitettu. Rahoitus tehostaa PrivX:n jatkokehitystä ja tukee erityisesti m2m-toimintojen, automaation ja IioT-toimintojen (teollinen esineiden internet) kehittämistä.Saatu rahoitus kirjataan aktivoitujen tuotekehitysmenojen vähennykseksi, josta se tuloutuu pienempien poistojen muodossa. Osa rahoituksesta kirjataan muihin liiketoiminnan tuottoihin syntyneiden kulujen suhteessa vuosina 2020-2022.Rahoitus...
Steve Hamil to Join Ebix as Global Chief Financial Officer
Written by Customer Service on . Posted in Public Companies.
JOHNS CREEK, Ga., April 08, 2020 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, e-governance and healthcare industries, today announces an addition to its leadership team with the appointment of Steven M. Hamil (Steve) as Executive Vice President and Global Chief Financial Officer. Steve joins Ebix from Regions Financial Corporation where he began in 2013 as Senior Vice President and Managing Director covering the technology, media and communication and defense and government services sectors. Steve has extensive experience in banking and capital markets with NationsBanc Capital Markets (now Bank of America) and Wachovia Capital Markets (Wells Fargo).Through his career, Steve has held senior financial and accounting leadership...
Athabasca Minerals Announces AMI RockChain Completion of $1 Million Order and Corporate Update
Written by Customer Service on . Posted in Public Companies.
CALGARY, Alberta, April 08, 2020 (GLOBE NEWSWIRE) — Athabasca Minerals Inc. (“AMI” or the “Corporation”) – TSXV:AMI – is pleased to announce:AMI RockChain’s recent achievement in completing a $1 million job order for the supply of specialized aggregates product (rail ballast) to a major customer with industrial operations in Central Alberta for a new transload facility.Corporate updates and progress regarding AMI Silica, AMI Aggregates (base division), as well as fiscal management in the face of COVID-19.The appointment of J. Robert Logan, MBA, ICD.D as Advisor to AMI’s Board of Directors with regard to the Corporation’s strategic business interests in 2020 and capital markets.Robert Beekhuizen, Chief Executive Officer, states: “Although we commonly face very challenging times right now, given the COVID-19 situation, AMI is adapting...
Även europeiska läkemedelsmyndigheten positiv till Corlines planerade fas 2-studie
Written by Customer Service on . Posted in Public Companies.
Den 11 mars 2020 var Corline inbjudet till rådgivningsmöte (Protocol Assistance) med den europeiska läkemedelsmyndigheten EMA för att diskutera bolagets planerade fas 2-studie för Renaparin®. Bolaget har nu erhållit EMA:s officiella mötesanteckningar där viktiga slutsatser är att EMA accepterar Corlines nuvarande prekliniska data och den pågående fas 1-studien – RENAPAIR 01 – som grund för fortsatt klinisk utveckling och marknadslansering, utan krav på kompletteringar. Råden från EMA linjerar med de som tidigare erhållits från FDA, vilket innebär att en gemensam fas 2-studie kan genomföras. Detta innebär en snabbare och mer kostnadseffektiv utvecklingsplan.Protocol Assistance-möte begärs av bolag och EMA håller sådana möten för att förbereda kliniska studier och efterföljande marknadsgodkännande i EU för nya läkemedel under utveckling....
NextCure to Present at the 19th Annual Needham Virtual Healthcare Conference
Written by Customer Service on . Posted in Public Companies.
BELTSVILLE, Md., April 08, 2020 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 19th Annual Needham Virtual Healthcare Conference on April 15th at 2:10 pm Eastern time.A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available approximately two hours after the event and archived on the website for 30 days.About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary...
Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic
Written by Customer Service on . Posted in Public Companies.
SALT LAKE CITY, April 08, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, announced today that due to the impact of the global COVID-19 pandemic, the company is withdrawing its fiscal year 2020 financial guidance.“Prior to mid-March we were experiencing volume trends consistent with our expectations across all products; however, recent social distancing guidelines have had a significant impact on test volume trends in late March and into the fiscal fourth-quarter,” said R. Bryan Riggsbee, interim president and CEO and chief financial officer at Myriad Genetics. “Our priority as an organization during the coronavirus pandemic has been to maintain business continuity and access to testing, while ensuring the safety of our employees and customers. As an organization we have taken...
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference
Written by Customer Service on . Posted in Public Companies.
ALPHARETTA, Ga., April 08, 2020 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview at the Needham Virtual Healthcare Conference on April 15, 2020 at 12:00 p.m. ET.A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.About Clearside BiomedicalClearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing...
Recordati Rare Diseases now holds Isturisa® European MA
Written by Customer Service on . Posted in Public Companies.
Recordati Rare Diseases is now the European Marketing Authorization holder of Isturisa® (osilodrostat) indicated for Adult patients with Endogenous Cushing’s Syndrome Paris, 8 April, 2020 – Recordati Rare Diseases today announces the transfer of the European Marketing Authorization of Isturisa® (osilodrostat). The transfer includes all EU member states plus the UK, Norway, Iceland and Liechtenstein.Isturisa® is authorized for the treatment of adult patients with Cushing’s syndrome. Isturisa® is a potent inhibitor of 11β-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis1. Isturisa® has demonstrated rapid and sustained normalization of cortisol levels in a significant proportion of adult patients with a manageable safety profile, making this a novel oral treatment option for patients with Cushing’s...
Intertape Polymer Group: COVID-19 Update
Written by Customer Service on . Posted in Public Companies.
MONTREAL and SARASOTA, Fla., April 08, 2020 (GLOBE NEWSWIRE) — Intertape Polymer Group Inc. (TSX:ITP) (“IPG” or the “Company”) today provided an update on its operations during the coronavirus COVID-19 (“COVID-19”) pandemic. The Company’s North American and European manufacturing operations are open and producing as a result of the essential nature of the end markets it serves.“Safety is our highest priority. As such, we are committed to ensuring a safe work environment for our employees, as well as their safety once they return home to their family,” said Greg Yull, President and CEO of IPG. “Our employees at the manufacturing facilities are performing work that is critical to the integrity of the supply chain for our end users that provide essential goods and services. The layout of our manufacturing lines allows for social distancing,...